The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant. (15th March 2022)

• Record Type: Journal Article
• Authors: Cohen, Stacey A.; Kasi, Anup; Hook, Nicole; Krainock, Michael; Budde, Griffin; Malashevich, Allyson Koyen; Meltzer, Jeffrey; Jelsema, Russ; Olshan, Perry; Billings, Paul R.; Aleshin, Alexey; Poklepovic, Andrew S.
• Other Names: Ku Seung-Yup Academic Editor.
• Is Part Of: Case reports in obstetrics and gynecology. Volume 2022(2022)
• Publication Date: 2022-03-15
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; Obstetrics; Gynecology; Genital Diseases, Female; Generative organs, Female -- Diseases; Gynecology; Obstetrics; Electronic journals; Periodicals; Periodicals; 618
• DOI: 10.1155/2022/9412201
• Languages: English
• ISSNs: 2090-6684

Abstract

Abstract : The number of pregnant women with cancer is on the rise. These patients and their providers encounter complex medical management decisions. Standard-of-care systemic therapy and radiological imaging can impair fetal development and affect viability. Conversely, insufficient monitoring and treatment can lead to cancer progression, compromising the health of the patient. Personalized and tumor-informed circulating tumor DNA (ctDNA) testing (Signatera™, bespoke mPCR NGS assay) is a validated, noninvasive blood test that can accurately assess cancer progression and tumor response to treatment ahead of radiological imaging, across solid tumors. In this case series of four patients, we explore the clinical utility of longitudinal ctDNA testing in the medical management of pregnant patients with solid tumors, to aid in informed decision-making for patients and providers.